A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets

NCT04601766 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2
DRUG: APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2

Sponsor

Asieris Pharmaceuticals (AUS) Pty Ltd.